Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.33−0.07 (-5.34%)
Close on Nov 17, 2026Market cap $124.65MP/E –Yield –
Innate Pharma r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €43.62M, down 16.1% from the year before. The highest annual figure on record is €69.56M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €43.62M | -16.1% |
| FY2024 | Dec 31, 2024 | €51.98M | -7.2% |
| FY2023 | Dec 31, 2023 | €56.02M | +8.4% |
| FY2022 | Dec 31, 2022 | €51.66M | +9.9% |
| FY2021 | Dec 31, 2021 | €47.00M | -5.4% |
| FY2020 | Dec 31, 2020 | €49.71M | -21.0% |
| FY2019 | Dec 31, 2019 | €62.90M | -9.6% |
| FY2018 | Dec 31, 2018 | €69.56M | +3.8% |
| FY2017 | Dec 31, 2017 | €67.00M | – |
See a number that looks wrong?